Roivant Sciences Ltd. - Common Shares (ROIV)
15.09
-0.19 (-1.24%)
NASDAQ · Last Trade: Sep 18th, 7:06 PM EDT
Via Benzinga · September 18, 2025
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said.
Via Stocktwits · September 17, 2025
The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.
Via The Motley Fool · September 17, 2025
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.
Via Benzinga · September 17, 2025
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · September 17, 2025
Via Benzinga · September 17, 2025
The company is working on a treatment for an autoimmune disease that affects the skin and muscles.
Via Investor's Business Daily · September 17, 2025
Investors were in a forgiving mood after Monday's dispiriting earnings release.
Via The Motley Fool · August 12, 2025
The distinctive biotech wasn't a sector favorite as the trading week began.
Via The Motley Fool · August 11, 2025
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings. These reports, ranging from cybersecurity and fintech to mining and life sciences, offer a crucial granular view into
Via MarketMinute · August 11, 2025

Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of President Donald Trump’s tari
Via Benzinga · May 29, 2025
The company is getting a new chief executive and a new chief financial officer amid sweeping changes.
Via Investor's Business Daily · April 21, 2025
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.
Via Benzinga · March 19, 2025
The companies reported positive results for their lead asset in patients with two rare diseases.
Via Investor's Business Daily · March 19, 2025

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.
Via The Motley Fool · February 10, 2025

Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while awaiting further clarity on trade policie
Via Benzinga · February 10, 2025

President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks.
Via MarketBeat · January 28, 2025